EXHIBIT B

win



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

Estimation Files	1 DATE PIRE	T NAMED INVENTION	ATTORNEY DOCKET NO.									
07/800,549 11/2	27/91 OSHLACK		B 91-318									
			EXAMMER									
SPRAD I												
STEINBERG & RASKI 1140 AVENUE OF TH												
NEW YORK, NY 100		ART UNIT PAPER NUMBER										
			1502									
This is a communication from the examinar COMMISSIONER OF PATERTS AND TRAI	in charge of year application. DEAMPKS		DATE MAILED: 04/30/92									
			•									
This application has been examined A shortened statutory period for response			27-1991. This action is made final.									
Failure to respond within the period for r	esponse will cause the application	month(s	deys from the date of this letter. 35 U.S.C. 133									
a contract of the contract of	ENT(S) ARE PART OF THIS AC											
1. Notice of References Cited by												
 I Notice of Art Cited by Applica 	ant, PTO-1449.	4. Notice of inf	tent Drawing, PTO-948. ormal Patent Application, Form PTO-152.									
5. Information on How to Effect	Drawing Changes, PTO-1474.	6. 🔲										
Part II SUMMARY OF ACTION		-										
1. A Claims			are pending in the application.									
Of the above, claims												
2. Claims			are withdrawn from consideration.									
			have been cancelled.									
3. L. Claims			are allowed,									
4. [X] Claims			are rejected.									
5. Claims		-	are objected to.									
6. Claims		are s	ubject to restriction or election requirement.									
			cceptable for examination purposes.									
8. Formal drawings are required in												
9. The corrected or substitute dra are acceptable. not a	twings have been received on cceptable (see explanation or No	otice re Patent Drawing, F										
10. The proposed additional or sub- examiner. disapproved by	stitute sheet(s) of drawings, filed the examiner (see explanation).	i on	has (have) been 🔲 approved by the									
11. The proposed drawing correction	on, filed on	_, has been 🔲 approve	d. D disapproved (see explanation).									
12. Acknowledgment is made of the	e claim for priority under U.S.C.	119. The certified conv ha	as 🗌 been received 🗎 not been received									
been filled in parent applica	tion, serial no.	; filed on										
13. Since this application appears t accordance with the practice un	o be in condition for allowance ender Ex parte Quayle, 193 i C.D.	except for formal matters, 11; 453 O.G. 213.	prosecution as to the merits is closed in									
14. Other												

Serial No. 800,549

1502 Art. Undit.

-2-

The following is a quotation of 35 U.S.C. § 103 which forms the basis for all obviousness rejections set forth in this Office action:

A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Subject matter developed by another person, which qualifies as prior art only under subsection (f) or (g) of section 102 of this title, shall not preclude patentability under this section where the subject matter and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person.

Claims 1-17 are rejected under 35 U.S.C. \$ 103 as being unpatentable over Goldie et al. U.S. 4,990,341 in view of Oshlack U.S. 4,861,598.

Goldie et al. teaches a controlled release oral, dosage form of an analgesic, hydromorphone, wherein the active ingredient is in a controlled release matrix. See claim 1. Goldie further teaches peak plasma levels attained between 2.25 and 3.75 hours per claim 4. The reference further teaches dosage ranges which are the same as those of applicants. Conventional matrix forming materials are disclosed in columns 3 and 4. Coating materials are shown at col. 4, lines 37-45. Conventional granulation processes are disclosed in the Examples. Although Goldie does not use oxycodone, both oxycodone and hydromorphone being

Serial No. 800,549

- 3 -

Art Unit 1502

derivatives of natural alkaloids with many structural similarities are considered interchangeable in the matrix compositions.

Oshlack is relied on for teaching matrix composition as those of applicants' wherein the active agent is oxycodone. See Example II. Claim 1.

It would have been obvious to one of ordinary skill in the art to use oxycodone in the Goldie et al. invention. The motivation to do so is suggested by a desirability to provide optimum drug bioavailability by controlled release from a matrix composition.

Claims 1-17 are rejected.

Any inquiry concerning this communication should be directed to James M. Spear at telephone number (703) 308-2351.

P

J. Spear/mbb April 27, 1992 THOUGHT A PAGE SUPERVISORY PATER EXAMINER ART UNIT 152

LO TOP AND BOTTOM EDGES, SNAP-APART AND DISCARD CARBON TO SEPARATE,

FORM PTO-892 U.S. DEPA (REV. 3-78) PATENT A							800549			1502			TACHMENT TO PAPER NUMBER							
NOTICE OF REFERENCES CITED APPLICANT(S) OSHLACK etal.																				
U.S. PATENT DOCUMENTS																				
*			D	ocı	ME	NT N	o.		DATI	DATE NAME							JB- ASS	FILING DATE IF APPROPRIATE		
	A	4	8	6	1	5	9	8	8-8	9	Oshlack				424	14	70			
	В	4	9	9	0	3	4	1	0		Go	die	die etali			484		H-89		
	C																			
	D																	<u> </u>		
	Ε																			
	F																			
	G	┞				Г	Γ													
	н	l				Ī								· ·			•			
	,	 	T	T		T								·······						
	J				T															
	к	Γ		Ī			Γ			, .			-							
		 .	-	. –	1	-U- ₁		.2	•	F	OREIGN	PATENT D	OCUMENT	ΓS	•					
		DOCUMENT NO.				DAT	E ·	cc	UNTRY	NAME		CLASS					PP. SPEC.			
	L																			
	м			ļ																
	N																			
	0																			
	Р																			
	a																			
					(TE	IE:	RRI	EFEREN	ICES	(Includi	ng Author	, Title, D	ate, Per	tinent Pa	ages, E	tc.}	•		
	R																			
L	Ľ																			
	s		····																	
	Ľ								· · · · · · · · · · · · · · · · · · ·											
	 									·										
	Ľ																			
	U																			
1				، فت	- Y	И.	<	ςρ,	ear	DATE	-18-	72								:
James M. Spear 4-18-92 1 *A copy of this reference is not being furnished with this office action.																				
(See Manual of Patent Examining Procedure, section 707.05 (a).)																				